MeSH term
Frequency | Condition_Probility | Androgen Antagonists/*therapeutic use | 2 | 5.0 |
Clinical Trials | 3 | 0.0 |
Humans | 79 | 0.0 |
Male | 36 | 0.0 |
Prostatic Neoplasms/*drug therapy | 5 | 14.0 |
Animals | 40 | 0.0 |
Body Weight/drug effects | 3 | 1.0 |
Diethylstilbestrol/*toxicity | 4 | 50.0 |
Female | 44 | 0.0 |
Mice | 18 | 0.0 |
Pregnancy | 9 | 0.0 |
Research Support, Non-U.S. Gov't | 38 | 0.0 |
Animals, Newborn | 4 | 0.0 |
Base Sequence | 6 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Diethylstilbestrol/*pharmacology | 7 | 43.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Molecular Sequence Data | 7 | 0.0 |
Calcium/*metabolism | 2 | 0.0 |
Estradiol/pharmacology | 3 | 1.0 |
Tumor Cells, Cultured | 4 | 0.0 |
Cell Line | 5 | 0.0 |
Dogs | 2 | 0.0 |
Diethylstilbestrol/pharmacology | 2 | 13.0 |
Reverse Transcriptase Polymerase Chain Reaction | 2 | 0.0 |
Tamoxifen/pharmacology | 3 | 3.0 |
Cell Line, Tumor | 2 | 0.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Ligands | 3 | 0.0 |
Protein Binding | 4 | 0.0 |
Receptors, Estrogen/metabolism | 2 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 29 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Cloning, Molecular | 2 | 0.0 |
Comparative Study | 13 | 0.0 |
Desmin/*genetics | 3 | 37.0 |
Adult | 13 | 0.0 |
Middle Aged | 18 | 0.0 |
Mutation | 3 | 0.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Cells, Cultured | 4 | 0.0 |
Dose-Response Relationship, Drug | 5 | 0.0 |
In Vitro | 2 | 0.0 |
Rats | 11 | 0.0 |
Rats, Sprague-Dawley | 3 | 0.0 |
Cell Division/drug effects | 4 | 0.0 |
Stromal Cells/drug effects | 2 | 20.0 |
Transfection | 2 | 0.0 |
Protein Conformation | 2 | 0.0 |
Binding, Competitive | 7 | 0.0 |
Carcinogens/*toxicity | 2 | 1.0 |
Hamsters | 5 | 0.0 |
Hyperplasia | 2 | 0.0 |
Breast Neoplasms/*drug therapy/pathology | 2 | 5.0 |
Diethylstilbestrol/administration & dosage/*therapeutic use | 2 | 100.0 |
Neoplasm Staging | 3 | 0.0 |
Treatment Outcome | 4 | 0.0 |
Diethylstilbestrol/*adverse effects | 2 | 40.0 |
Prospective Studies | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Thromboembolism/chemically induced | 2 | 28.0 |
United States | 4 | 0.0 |
Aged | 9 | 0.0 |
Aged, 80 and over | 3 | 0.0 |
Diethylstilbestrol/*administration & dosage | 3 | 100.0 |
Testosterone/blood | 3 | 0.0 |
Diethylstilbestrol/administration & dosage/*pharmacology | 2 | 100.0 |
Drug Combinations | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Ovariectomy | 2 | 1.0 |
*Prenatal Exposure Delayed Effects | 3 | 6.0 |
Age Factors | 3 | 0.0 |
Reference Values | 3 | 0.0 |
Structure-Activity Relationship | 2 | 0.0 |
Diethylstilbestrol/*therapeutic use | 3 | 50.0 |
Metabolic Clearance Rate | 2 | 0.0 |
*Orchiectomy | 2 | 11.0 |
Prognosis | 3 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 5 | 0.0 |
Tissue Distribution | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 3 | 0.0 |
Drug Administration Schedule | 2 | 0.0 |
English Abstract | 5 | 0.0 |
*Chromosomes, Human, Pair 2 | 2 | 0.0 |
Genetic Markers | 3 | 0.0 |
Leprosy/*genetics | 2 | 22.0 |
Lod Score | 2 | 0.0 |
Pedigree | 4 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Drug Synergism | 2 | 0.0 |
Cattle | 2 | 0.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Blood Platelets/*chemistry | 2 | 5.0 |
Leukocyte Count | 2 | 0.0 |
Kinetics | 8 | 0.0 |
Species Specificity | 2 | 0.0 |
Mice, Inbred BALB C | 5 | 0.0 |
Radioimmunoassay | 4 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Neoplasms/chemically induced | 2 | 16.0 |
Adolescent | 2 | 0.0 |
Diethylstilbestrol/administration & dosage/therapeutic use | 2 | 66.0 |
Binding Sites, Antibody | 2 | 0.0 |
Orchiectomy | 2 | 1.0 |
*Chemotaxis, Leukocyte | 2 | 2.0 |
*Complement 3a/*analogs & derivatives | 3 | 15.0 |
*Complement Activation | 2 | 0.0 |
Phagocytosis | 2 | 0.0 |
Complement 3a | 2 | 8.0 |
Guinea Pigs | 2 | 0.0 |
Indomethacin/pharmacology | 2 | 0.0 |
Sister Chromatid Exchange/*drug effects | 2 | 6.0 |
Follicle Stimulating Hormone/blood | 3 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Diethylstilbestrol/*metabolism | 2 | 100.0 |
Estradiol/metabolism | 2 | 2.0 |
Sex Hormone-Binding Globulin/metabolism | 2 | 0.0 |
Cytosol/analysis | 2 | 6.0 |
Receptors, Estrogen/*analysis | 3 | 1.0 |
Receptors, Progesterone/*analysis | 2 | 0.0 |
Syndrome | 2 | 0.0 |
Cell Aggregation | 2 | 1.0 |
Complement 5a | 4 | 12.0 |
Complement 5a, des-Arginine | 2 | 28.0 |
Tamoxifen/therapeutic use | 2 | 3.0 |
Receptors, Estrogen/analysis | 2 | 0.0 |
Cell Survival/drug effects | 2 | 0.0 |
Castration | 2 | 4.0 |
Organ Size/drug effects | 2 | 2.0 |
Binding Sites | 2 | 0.0 |
Cyclooxygenase Inhibitors | 2 | 12.0 |
Neutrophils/*immunology | 2 | 1.0 |
Rabbits | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Estradiol/*metabolism | 2 | 3.0 |
alpha-Fetoproteins/metabolism | 2 | 2.0 |
Neoplasms/*chemically induced | 2 | 8.0 |
Diethylstilbestrol/*chemistry | 2 | 100.0 |
